3-(tert-butyloxycarbonyl-methyl-amino)-N-(9H-purin-6-yl)propionamide | 1202814-80-9

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 3-(tert-butyloxycarbonyl-methyl-amino)-N-(9H-purin-6-yl)propionamide
• 英文别名: tert-butyl N-ethyl-N-[3-oxo-3-(7H-purin-6-ylamino)propyl]carbamate
• CAS: 1202814-80-9
• 化学式: C₁₅H₂₂N₆O₃
• 分子量: 334.378
• InChiKey: PZUYYUCCWZBFGW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  24
• 可旋转键数：
  7
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.53
• 拓扑面积：
  113
• 氢给体数：
  2
• 氢受体数：
  6

文献信息

• Adenine receptor ligands
  申请人：Rheinische Friedrich-Wilhelms-Universität Bonn

  公开号：EP2141166A1

  公开（公告）日：2010-01-06

  The invention relates to adenine receptor ligands useful for treating, alleviating and/or preventing diseases and disorders related to adenine receptor function as well as pharmaceutical compositions comprising such compounds and methods for preparing such compounds. The invention is further directed to the use of these compounds, alone or in combination with other therapeutic agents, for the alleviating, preventing and/or treating diseases and disorders, especially the use as antinociceptive or neuroprotective drugs.

  该发明涉及腺嘌呤受体配体，用于治疗、缓解和/或预防与腺嘌呤受体功能相关的疾病和障碍，以及包括这些化合物的药物组合物和制备这些化合物的方法。该发明进一步涉及使用这些化合物，单独或与其他治疗剂联合使用，用于缓解、预防和/或治疗疾病和障碍，特别是作为镇痛或神经保护药物的用途。
• ADENINE RECEPTOR LIGANDS
  申请人：MUeller Christa

  公开号：US20110288106A1

  公开（公告）日：2011-11-24

  The invention relates to adenine receptor ligands useful for treating, alleviating and/or preventing diseases and disorders related to adenine receptor function as well as pharmaceutical compositions comprising such compounds and methods for preparing such compounds. The invention is further directed to the use of these compounds, alone or in combination with other therapeutic agents, for the alleviating, preventing and/or treating diseases and disorders, especially the use as antinociceptive or neuroprotective drugs.
• [EN] ADENINE RECEPTOR LIGANDS<br/>[FR] LIGANDS DES RÉCEPTEURS DE L'ADÉNINE
  申请人：UNIV BONN

  公开号：WO2010000429A1

  公开（公告）日：2010-01-07

  The invention relates to adenine receptor ligands useful for treating, alleviating and/or preventing diseases and disorders related to adenine receptor function as well as pharmaceutical compositions comprising such compounds and methods for preparing such compounds. The invention is further directed to the use of these compounds, alone or in combination with other therapeutic agents, for the alleviating, preventing and/or treating diseases and disorders, especially the use as antinociceptive or neuroprotective drugs.